GLENMARK — Glenmark Pharmaceuticals Balance Sheet
0.000.00%
- IN₹549.22bn
- IN₹532.31bn
- IN₹133.22bn
- 70
- 16
- 87
- 63
Annual balance sheet for Glenmark Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | C2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 11,381 | 14,105 | 11,592 | 16,583 | 16,757 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 34,152 | 39,359 | 44,884 | 29,990 | 41,811 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 73,596 | 82,823 | 84,236 | 74,281 | 92,955 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 41,756 | 46,117 | 41,951 | 35,375 | 38,614 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 156,036 | 170,833 | 193,717 | 143,586 | 160,496 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 42,010 | 46,894 | 45,462 | 58,186 | 59,670 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 85,390 | 79,966 | 98,978 | 65,107 | 72,001 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 70,646 | 90,866 | 94,739 | 78,479 | 88,494 |
| Total Liabilities & Shareholders' Equity | 156,036 | 170,833 | 193,717 | 143,586 | 160,496 |
| Total Common Shares Outstanding |